MON, 26 November 2018 |
|
|
|
|
|
17:30 - 19:00 |
Welcome reception in the Dan Hotel |
|
|
|
|
TUE, 27 November 2018 |
|
|
|
|
|
08:15 - 09:00 |
Registration |
|
09:00 - 09:05 |
Opening |
|
|
|
|
|
Experimental Uveitis Models in 2018 |
|
|
|
|
09:05 - 09:25 |
Regulation of Th17 response by IL-17: implications for autoimmunity |
Rachel Caspi |
09:25 - 09:45 |
Lessons from experimental rat models for chronic and relapsing autoimmune uveitis |
Gerhild Wildner |
09:45 - 10:05 |
Of mice and men and women |
James Rosenbaum |
10:05 - 10:20 |
Discussion |
|
|
|
|
|
The Role of Microbiome in Uveitis |
|
|
|
|
10:45 - 11:00 |
Welcome to the World of Microbiota |
Nida Sen |
11:00 - 11:18 |
Microbiome and the Eye-the good and the bad |
Rachel Caspi |
11:18 - 11:38 |
Microbiome and Tuberculosis |
Florian Hoelzl |
11:38 - 11:56 |
Microbiome and HLA-B27 |
James Rosenbaum |
11:56 - 12:16 |
Virome and the Eye |
Jolanda D.F de Groot-Mijnes |
12:16 - 12:30 |
Discussion |
|
|
|
|
|
Multimodal Imaging (MMI) for Inflammatory Outer Retinopathies |
|
|
|
|
13:30 - 13:42 |
What have we learned from MMI about inflammatory outer retinopathies |
Michal Kramer |
13:42 - 13:54 |
Insights to outer retinopathies from OCTA and Adaptive Optics |
Padmamalini Mahendradas |
13:54 - 14:04 |
Clues for inflammation by MMI of rarest entities |
Orly Gal-Or |
14:04 - 14:16 |
Clinical application of Artificial Intelligence and Machine Learning |
Noam Bresiz |
14:16 - 14:26 |
The way to use Artificial Intelligence and machine learning in Uveitis Diagnosis |
Antoine Brezin |
14:26 - 14:36 |
How MMI changes our management of inflammatory outer retinopathies |
Padmamalini Mahendradas |
14:36 - 14:45 |
Discussion |
|
|
|
|
15:15 - 16:15 |
Controversies |
|
|
|
|
|
1. Systemic vs intraocular steroid therapy for acute toxoplasmic retinochoroiditis |
pro systemic: Emmett Cunningham pro intraocular: Rubens Belfort |
|
2. Biologics vs immunosuppressives as first line treatment for JIA-induced uveitis |
pro Biologics: Athimalaipet V. Ramanan pro Immunosuppressives: Debra Goldstein |
|
3. Treatment of Behcet´s Disease: anti-TNF vs interferon alpha |
pro: anti-TNF-alpha: Shiri Shulman pro: interferon alpha: Manfred Zierhut |
|
|
|
|
Progression Markers |
|
|
|
|
16:15 - 16:25 |
Progression markers of Vogt Koyanagi Haradas Disease |
Nobuyoshi Kitaichi |
16:25 - 16:35 |
Biomarkers for increased risk of developing uveitis in JIA |
Joke de Boer |
16:35 - 16:45 |
Laser flare photometry can predict a recurrence in Behçet-uveitis |
Nilüfer Yalcindag |
16:45 - 17:00 |
Discussion |
|
|
|
|
WED, 28 November 2018 |
|
|
|
|
|
08:30 - 09:00 |
Registration (new participants) |
|
|
|
|
|
Tuberculosis - From Infection to Inflammation |
|
|
|
|
09:00 - 09:12 |
Immunology of general TB infection |
Florian Hoelzl |
09:12 - 09:24 |
Immunology of ocular TB infection |
Soumyava Basu |
09:24 - 09:36 |
Update of the the COTS-studies |
Reema Bansal |
09:36 - 09:48 |
Clinical spectrum of “inflammatory” TB |
Vasconcellos-Santos Daniel |
09:48 - 10:00 |
Quantiferon testing in endemic vs. non-endemic areas |
Soon Phaik Chee |
10:00 - 10:15 |
Discussion |
|
|
|
|
|
Preparing for Intraocular Surgery in Uveitis Patients |
|
|
|
|
10:45 - 11:00 |
General principles of medical preparation for intraocular surgery in uveitis |
|
11:00 - 11:15 |
Intra- and perioperative care during cataract surgery |
|
11:15 - 11:30 |
Preparing for glaucoma drainage and vitrectomy in uveitis |
|
11:30 - 12:30 |
Round Table |
Moderator: Nicholas Jones Cristina Muccioli, Nisha Acharya, Matthias Becker |
|
|
|
|
Uveitis Related Macular Edema |
|
|
|
|
13:30 -13:50 |
Differences between Uveitis macular edema and other etiologies |
Francine Behar Cohen |
13:50 - 14:00 |
Role of Cytokines in uveitis related CME |
Marina Mesquida |
14:00 - 14:15 |
Macular edema-what have the MUST trials taught us |
Sue Lightman |
14:15 - 14:30 |
Options for treatment of uveitis related CME |
Marina Mesquida |
14:30 - 14:40 |
Biologics and uveitic CME |
Oren Tomkins |
14:40 - 15:00 |
Discussion |
|
|
|
|
|
Future Protocols for Uveitis Trials |
|
|
|
|
15:30 - 15:35 |
Introduction |
Philip Murray |
15:35 - 15:50 |
The Problem of outcome measurements in uveitis trials |
Nisha Acharya |
15:50 - 06:03 |
Clinical trials in uveitis-The Industry Perspective |
Ron Neuman |
16:03 - 16:16 |
Clinical trials in uveitis-The Reading Center Perspective |
Marion Munk |
16:16 - 16:29 |
Why previous uveitis trials often failed |
James Rosenbaum |
16:29 - 17:00 |
Round Table: What would be your ideal uveitis trial |
Moderator: Philip Murray |
|
|
|
THU, 29. November 2018 |
|
|
|
|
|
08:30 - 09:00 |
Registration (new participants) |
|
|
|
|
|
Biologic Agents for Uveitis |
|
|
|
|
09:00 - 09:12 |
Definition of “Failure” under biologic drugs |
Debra Goldstein |
09:12 - 09:24 |
Biologics inducing uveitis |
Manfred Zierhut |
09:24 - 09:36 |
Side effects of biologics and biosimilars |
Martin van Hagen |
09:36 - 09:48 |
Off label biologics as the next step |
Eric Suhler |
09:48 - 10:15 |
Discussion |
|
|
|
|
10:45 - 12:00 |
Case Reports |
Chairs: Careen Lowder, Massimo Accorinti, Zohar Habot-Wilner |
|
|
Mystery Cases - Israeli Uveitis Group |
|
|
|
12:00 - 12:30 |
Presentation of the best 5 Posters |
|
|
|
|
|
Uveitis in Immune Incompetent Patients |
|
|
|
|
13:30 - 13:42 |
AIDS associated Uveitis in 2018 |
Jyotirmay Biswas |
13:42 - 13:54 |
Role of CMV in immune incompetence |
Alejandra dela Torre |
13:54 - 14:06 |
Post-Transplantation-Lymphoproliferative disorders |
Manfred Zierhut |
14:06 - 14:18 |
Immune mediated ocular toxicity following the use of Immune Checkpoint Inhibitors for malignancy |
Nida Sen |
14:18 - 14:30 |
Carcinoma-associated Uveitis |
Radgonde Amer |